Regadenoson for myocardial perfusion scintigraphy

Bibliography

• Loong CY, Anagnostopoulos C. Diagnosis of coronary artery disease by radionuclide myocardial perfusion imaging. Heart 2004;90(Suppl 5):v2-9
   PubMed Web of Science ®Google Scholar
• Wilson RF, Wyche K, Christensen BV, Effects of adenosine on human coronary arterial circulation. Circulation 1990;82:1595-606
   PubMed Web of Science ®Google Scholar
• Cerqueira MD, Verani MS, Schwaiger M, Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry. J Am Coll Cardiol 1994;23:384-9
   PubMed Web of Science ®Google Scholar
• Fredholm BB, IJzerman AP, Jacobson KA, International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001;53:527-52
   PubMed Web of Science ®Google Scholar
• Belardinelli L, Shryock JC, Snowdy S, The A2A adenosine receptor mediates coronary vasodilation. J Pharmacol Exp Ther 1998;284:1066-73
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Mavrogeni SI, Forbat SM, Adenosine combined with dynamic exercise for myocardial perfusion imaging. J Am Coll Cardiol 1995;25:1300-9
   PubMed Web of Science ®Google Scholar
• Thomas GS, Prill NV, Majmundar H, Treadmill exercise during adenosine infusion is safe, results in fewer adverse reactions, and improves myocardial perfusion image quality. J Nucl Cardiol 2000;7:439-46
   PubMed Web of Science ®Google Scholar
• Glover DK, Ruiz M, Yang JY, Pharmacological stress thallium scintigraphy with 2-cyclohexylmethylidene hydrazinoadenosine (WRC-0470). A novel, short-acting adenosine A2A receptor agonist. Circulation 1996;94:1726-32
   PubMed Web of Science ®Google Scholar
• Alberti C, Monopoli A, Casati C, Mechanism and pressor relevance of the short-term cardiovascular and renin excitatory actions of the selective A2A-adenosine receptor agonists. J Cardiovasc Pharmacol 1997;30:320-4
   PubMed Web of Science ®Google Scholar
• Gao Z, Li Z, Baker SP, Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists. J Pharmacol Exp Ther 2001;298:209-18
   PubMed Web of Science ®Google Scholar
• Zhao G, Linke A, Xu X, Comparative profile of vasodilation by CVT-3146, a novel A2A receptor agonist, and adenosine in conscious dogs. J Pharmacol Exp Ther 2003;307:182-9
   PubMed Web of Science ®Google Scholar
• Zablocki J, Palle V, Blackburn B, 2-substituted pi system derivatives of adenosine that are coronary vasodilators acting via the A2A adenosine receptor. Nucleosides Nucleotides Nucleic Acids 2001;20:343-60
   PubMed Web of Science ®Google Scholar
• Glover DK, Okada RD. Myocardial kinetics of Tc-MIBI in canine myocardium after dipyridamole. Circulation 1990;81:628-37
   PubMed Web of Science ®Google Scholar
• Okada RD, Williams SJ, Glover DK, Dragatokis D. Cardiac imaging and myocardial kinetics of technetium-tertiary butyl-isonitrile during dipyridamole-induced hyperemia. Am Heart J 1988;116:979-88
   PubMed Web of Science ®Google Scholar
• Trochu JN, Zhao G, Post H, Selective A2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: potential for use in myocardial perfusion imaging. J Cardiovasc Pharmacol 2003;41:132-9
   PubMed Web of Science ®Google Scholar
• Lieu HD, Shryock JC, von Mering GO, Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol 2007;14:514-20
   PubMed Web of Science ®Google Scholar
• Gordi T, Frohna P, Sun HL, A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin Pharmacokinet 2006;45:1201-12
   PubMed Web of Science ®Google Scholar
• Cerqueira MD, Nguyen P, Staehr P, ; on behalf of the ADVANCE-MPI Trial Investigators. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging: integrated ADVANCE-MPI Trial results. J Am Coll Cardiol Img 2008;1:307-16
   Web of Science ®Google Scholar
• Gordi T, Blackburn B, Lieu H. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. J Clin Pharmacol 2007;47:825-33
   PubMed Web of Science ®Google Scholar
• Iskandrian AE, Bateman TM, Belardinelli L, Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007;14:645-58
   PubMed Web of Science ®Google Scholar
• Dhalla AK, Wong MY, Wang WQ, Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther 2006;316:695-702
   PubMed Web of Science ®Google Scholar
• Henzlova M, Cerqueira MD, Hansen C, ASNC imaging guidelines for nuclear cardiology procedures: stress protocols and tracers. American Society of Nuclear Cardiology (ASNC) 2009. Available from: http://www.asnc.org/section_73.cfm. [1 Februrary 2010]
   Google Scholar
• Mahmarian JJ, Cerqueira MD, Iskandrian AE, Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial. JACC Cardiovasc Imaging 2009;2:959-68
   PubMed Web of Science ®Google Scholar
• Hendel RC, Bateman TM, Cerqueira MD, Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol 2005;46:2069-75
   PubMed Web of Science ®Google Scholar
• Reyes E, Standbridge K, Nguyen P, A comparison of the safety profile and tolerability of regadenoson and adenosine for myocardial perfusion scintigraphy in older patients [abstract]. J Nucl Cardiol 2007;14:S24
   Google Scholar
• Standbridge K, Reyes E, Nguyen P, The safety and efficacy of regadenoson myocardial perfusion scintigraphy in women [abstract]. J Nucl Cardiol 2007;14:S75
   PubMedGoogle Scholar
• Thomas GS, Thompson RC, Miyamoto MI, The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A(2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 2009;16:63-72
   PubMed Web of Science ®Google Scholar
• Shryock JC, Snowdy S, Baraldi PG, A2A-adenosine receptor reserve for coronary vasodilation. Circulation 1998;98:711-18
   PubMed Web of Science ®Google Scholar
• Shryock JC, Wu Y. Receptor reserve is large for coronary hyperemia induced by regadenoson, a moderate affinity A2a-adenosine receptor agonist and vasodilator for cardiac perfusion imaging [abstract]. J Nucl Cardiol 2007;14:S63
   Google Scholar
• Cushley MJ, Tattersfield AE, Holgate ST. Inhaled adenosine and guanosine on airway resistance in normal and asthmatic subjects. 1983. Br J Clin Pharmacol 2004;58:S751-5
   PubMed Web of Science ®Google Scholar
• Zhong H, Belardinelli L, Maa T, A(2B) adenosine receptors increase cytokine release by bronchial smooth muscle cells. Am J Respir Cell Mol Biol 2004;30:118-25
   PubMed Web of Science ®Google Scholar
• Obiefuna PC, Batra VK, Nadeem A, A novel A1 adenosine receptor antagonist, L-97-1 [3-[2-(4-aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxy-ethyl)-amino]- ethyl}-1-propyl-3,7-dihydro-purine-2,6-dione], reduces allergic responses to house dust mite in an allergic rabbit model of asthma. J Pharmacol Exp Ther 2005;315:329-36
   PubMed Web of Science ®Google Scholar
• Van Den BM, Meijer RJ, Kerstjens HA, PC(20) adenosine 5′-monophosphate is more closely associated with airway inflammation in asthma than PC(20) methacholine. Am J Respir Crit Care Med 2001;163:1546-50
   PubMed Web of Science ®Google Scholar
• Zhong H, Shlykov SG, Molina JG, Activation of murine lung mast cells by the adenosine A3 receptor. J Immunol 2003;171:338-45
   PubMed Web of Science ®Google Scholar
• Reyes E, Loong CY, Wechalekar K, Side effect profile and tolerability of adenosine myocardial perfusion scintigraphy in patients with mild asthma or chronic obstructive pulmonary disease. J Nucl Cardiol 2007;14:827-34
   PubMed Web of Science ®Google Scholar
• van Gaal WJ, Couthino B, Chan M, Allman KC. The safety and tolerability of adenosine in patients with obstructive airways disease. Int J Cardiol 2008;128:436-8
   PubMed Web of Science ®Google Scholar
• Sundram F, Notghi A, Smith NB. Pharmacological stress myocardial perfusion scintigraphy: use of a modified adenosine protocol in patients with asthma. Nucl Med Commun 2009;30:217-25
   PubMed Web of Science ®Google Scholar
• Thomas GS, Tammelin BR, Schiffman GL, Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol 2008;15:319-28
   PubMed Web of Science ®Google Scholar
• Leaker BR, O'Connor B, Hansel TT, Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial. J Nucl Cardiol 2008;15:329-36
   PubMed Web of Science ®Google Scholar
• Reyes E, Loong CY, Harbinson M, High-dose adenosine overcomes the attenuation of myocardial perfusion reserve caused by caffeine. J Am Coll Cardiol 2008;52:2008-16
   PubMed Web of Science ®Google Scholar
• Gaemperli O, Schepis T, Koepfli P, Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by positron emission tomography: a randomized, double-blind, placebo-controlled crossover trial. J Am Coll Cardiol 2008;51:328-9
   PubMed Web of Science ®Google Scholar
• Zhao G, Messina E, Xu X, Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor agonist. J Cardiovasc Pharmacol 2007;49:369-75
   PubMed Web of Science ®Google Scholar